Adaptogenics Health Corp. Announces Upcoming Annual General and Special Meeting
Adaptogenics Health Corp. has scheduled its Annual General and Special (AGS) meeting for December 18, 2026, with a record date of November 13, 2026.
Stocks · News reference
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adaptive Biotechnologies Insider Sold Shares Worth $879,088
An insider at Adaptive Biotechnologies Corporation has sold company shares valued at approximately $879,088.
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
Salesforce vs. International Business Machines: Which Technology Stock Is a Better Buy in 2026?
Salesforce and IBM present contrasting investment profiles in 2026. Salesforce leads in growth (13.5% vs 4.5% average revenue growth) and profitability (21.5% operating margin), while IBM offers better valuation metrics (3.4x P/S ratio vs 4.7x) and higher dividend yield (2.66% vs 0.70%). The choice depends on investor preference: growth-oriented investors favor Salesforce, while value investors may prefer IBM.
Why Braze Stock Soared This Week
Salesforce agreed to acquire customer engagement software provider Braze for $5.66 billion at $47.50 per share in cash, representing a 58% premium over its pre-announcement price. The stock surged 56.3% following the announcement. However, analysts suggest current investors should cash out now rather than hold for deal closure in 2027, as the <4% upside from current levels offers minimal returns comparable to money market rates while carrying deal completion risk.